TIGER-3: A phase 3 multinational open-label randomized study of rociletinib vs investigator-choice chemotherapy in patients (pts) with epidermal growth factor receptor mutant-positive (EGFRm) non-small cell lung cancer (NSCLC) progressing on prior EGFR tyrosine kinase inhibitor (TKI) therapy and doublet chemotherapy. Yang, J., Popat, S., Novello, S., Groen, H. M., Perol, M., Felip, E., Griesinger, F., Reckamp, K. L., Lee, J., Smit, E. F., Blakely, C. M., Akerley, W. L., Kim, Y., Bazhenova, L., Califano, R., Hall, R., Georgiou, P., Isaacson, J. D., Golsorkhi, T., Wakelee, H. A. AMER SOC CLINICAL ONCOLOGY. 2016

View details for DOI 10.1200/JCO.2016.34.15_suppl.TPS9106

View details for Web of Science ID 000404711506252